Relmada Therapeutics (RLMD) Cash & Equivalents (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Cash & Equivalents data on file, last reported at $9.8 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $9.8 million, up 750.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.8 million (up 750.34% YoY), and the FY2025 annual result was $3.5 million, down 9.35% from the prior year.
• Cash & Equivalents grew to $9.8 million in Q1 2026 per RLMD's latest filing, from $3.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $44.9 million in Q1 2022 and troughed at $1.1 million in Q1 2025.
• A 5-year average of $12.4 million and a median of $4.1 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents jumped 1081.23% in 2022, then slumped 95.38% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $5.4 million in 2022, then fell by 24.17% to $4.1 million in 2023, then declined by 5.73% to $3.9 million in 2024, then retreated by 9.35% to $3.5 million in 2025, then surged by 179.6% to $9.8 million in 2026.
• Business Quant data shows RLMD's Cash & Equivalents at $9.8 million in Q1 2026, $3.5 million in Q4 2025, and $1.4 million in Q3 2025.